Biomarker panel for sepsis encephalopathy

A method of improving diagnosis of sepsis-associated encephalopathy (SAE) in a subject diagnosed with or suspected of having sepsis, comprising:

• (a) collecting a biological sample from the subject within about 6 hours from arrival at a treatment facility, within about 72 hours from arrival at a treatment facility, or both;
• and
• (b) testing the sample or samples for the presence or amount of a first biomarker and a second biomarker,
• wherein the first biomarker is selected from the group consisting of GFAP, UCH-L1, NF-L, and pNF-H;
• and the second biomarker is selected from the group consisting of GFAP, NF-L, pNF-H, UCH-L1, Tau, secretogranin, MBP, αII-spectrin, SBDP, NSE, BDNF, and Pro-BDNF;
• and
• (c) determining whether the subject has SAE or an increased likelihood thereof based on at least in part of the presence or amount of the first and second biomarkers measured in (b).